Loading...

CTXR CITIUS PHARMACEUTICALS INC US FDA Inspections 8-K Filing

CTS

CTXR

CITIUS PHARMACEUTICALS INC

(CTXR)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Increase in authorized shares

Debt-Equity Swaps

Voluntary Delisting

Financial Statements

Asset Acquisition

Securities Offering

Annual Meeting Results

Quarterly Results

New Coding Announcement

Securities Offering

Product Launch Update

Nasdaq Compliance

FDA Meeting Update

Nasdaq Compliance

Management Changes

Payment Deferral

Nasdaq Delisting Notice

Merger Completion

Q2 Earnings Report

Clinical Trial Results

Earnings Reports

Securities Purchase Agreement

Extension of Warrants

FDA Acceptance of Biologics...

Delisting Notice

Earnings Reports

Resubmission of BLA for LYM...

Nomination of Robert J. Smi...

Annual Meeting Announcement

Results of Operations and F...

Merger Agreement

Corporate Presentation

Earnings Reports

Clinical Trial Milestone

FDA Response Letter

Earnings Reports

Securities Purchase Agreement

Clinical Trial Advancement

Enrollment Completion in Ph...

Earnings Reports

Annual Meeting of Stockholders

External Links:

Citius Pharmaceuticals, Inc. received a complete response letter from the FDA for LYMPHIR for the treatment of cutaneous T-cell lymphoma.

AI Assistant

CITIUS PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.